Literature DB >> 20638310

Reaching out to the lost generation of adults with early-treated phenylketonuria (PKU).

Barbara K Burton1, Lauren Leviton.   

Abstract

Many adult patients with phenylketonuria (PKU) are no longer receiving treatment for their disorder despite mounting evidence that elevated blood phenylalanine levels are associated with impairments of brain function manifested by neurocognitive deficits and psychiatric symptoms. An outreach program was established in a single PKU clinic with the goal of bringing "wayward" adults back into treatment. In a clinic with 152 active patients, another 162 records were identified of patients who had been previously treated and had not transferred to another clinic. 47 of these patients could not be located. Of the remaining 115, a total of 63 were re-engaged and received education, either through individual telephone encounters or attendance at adult educational programs. Thus far, 21 patients have returned to treatment. Obstacles to treatment for many patients include inadequate insurance coverage and lack of understanding of the significance of the diagnosis of PKU among patients off treatment for many years. The social, emotional and psychiatric symptoms of the disorder itself are perhaps the greatest barrier to successful re-introduction to treatment. This experience confirms that there are large numbers of adult patients with PKU who are not currently receiving any care for their disorder. Reaching them and re-engaging them in treatment will be a significant challenge and will require a multifaceted effort.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638310     DOI: 10.1016/j.ymgme.2010.06.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

Review 1.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

2.  Maternal Phenylketonuria: Long-term Outcomes in Offspring and Post-pregnancy Maternal Characteristics.

Authors:  S E Waisbren; F Rohr; V Anastasoaie; M Brown; D Harris; A Ozonoff; S Petrides; A Wessel; H L Levy
Journal:  JIMD Rep       Date:  2015-02-25

3.  Management of adult patients with phenylketonuria: survey results from 24 countries.

Authors:  Friedrich K Trefz; Francjan J van Spronsen; Anita MacDonald; François Feillet; Ania C Muntau; Amaya Belanger-Quintana; Alberto Burlina; Mübeccel Demirkol; Marcello Giovannini; Christoph Gasteyger
Journal:  Eur J Pediatr       Date:  2014-12-06       Impact factor: 3.183

Review 4.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 5.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

6.  Neuroradiological findings of an adolescent with early treated phenylketonuria: is phenylalanine restriction enough?

Authors:  Mayara Thays Beckhauser; Mirella Maccarini Peruchi; Gizele Rozone de Luca; Katia Lin; Sofia Esteves; Laura Vilarinho; Jaime Lin
Journal:  Clin Pract       Date:  2011-05-03

7.  Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.

Authors:  Roman Trepp; Raphaela Muri; Stephanie Abgottspon; Lenka Bosanska; Michel Hochuli; Johannes Slotboom; Christian Rummel; Roland Kreis; Regula Everts
Journal:  Trials       Date:  2020-02-13       Impact factor: 2.279

8.  Attention Deficit Disorder with Hyperactivity Symptoms in Early-Treated Phenylketonuria Patients.

Authors:  Mayara Thays Beckhauser; Marcella Beghini Mendes Vieira; Betine Moehlecke Iser; Gisele Rozone DE Luca; Marcelo Rodrigues Masruha; Jaime Lin; Emilio Luiz Streck
Journal:  Iran J Child Neurol       Date:  2020

9.  Implementing a Transition Program from Paediatric to Adult Services in Phenylketonuria: Results After Two Years of Follow-Up with an Adult Team.

Authors:  Maria Peres; Manuela F Almeida; Élia J Pinto; Carla Carmona; Sara Rocha; Arlindo Guimas; Rosa Ribeiro; Esmeralda Martins; Anabela Bandeira; Anita MacDonald; Júlio C Rocha
Journal:  Nutrients       Date:  2021-02-28       Impact factor: 5.717

Review 10.  Newborn screening 50 years later: access issues faced by adults with PKU.

Authors:  Susan A Berry; Christine Brown; Mitzie Grant; Carol L Greene; Elaina Jurecki; Jean Koch; Kathryn Moseley; Ruth Suter; Sandra C van Calcar; Judy Wiles; Stephen Cederbaum
Journal:  Genet Med       Date:  2013-03-07       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.